Vanguard Group
VYGR icon

Vanguard Group’s Voyager Therapeutics VYGR Stock Holding History

Vanguard Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$12.8M Buy
3,266,484
+16,418
+0.5% +$72.6K ﹤0.01% 2836
2025
Q3 		$15.2M Buy
3,250,066
+40,147
+1% +$145K ﹤0.01% 2760
2025
Q2 		$9.98M Sell
3,209,919
-1,164
-0% -$3.75K ﹤0.01% 2903
2025
Q1 		$10.9M Sell
3,211,083
-4,358
-0.1% -$20.4K ﹤0.01% 2803
2024
Q4 		$18.2M Buy
3,215,441
+29,014
+0.9% +$187K ﹤0.01% 2627
2024
Q3 		$18.6M Buy
3,186,427
+147,863
+5% +$1.08M ﹤0.01% 2624
2024
Q2 		$24M Sell
3,038,564
-193,134
-6% -$1.62M ﹤0.01% 2475
2024
Q1 		$30.1M Buy
3,231,698
+702,030
+28% +$5.93M ﹤0.01% 2395
2023
Q4 		$21.4M Buy
2,529,668
+47,711
+2% +$346K ﹤0.01% 2565
2023
Q3 		$19.2M Buy
2,481,957
+6,131
+0.2% +$56K ﹤0.01% 2564
2023
Q2 		$28.3M Buy
2,475,826
+511,146
+26% +$5.29M ﹤0.01% 2440
2023
Q1 		$15.1M Buy
1,964,680
+9,508
+0.5% +$75.6K ﹤0.01% 2727
2022
Q4 		$11.9M Buy
1,955,172
+58,358
+3% +$332K ﹤0.01% 2873
2022
Q3 		$11.2M Sell
1,896,814
-93,073
-5% -$596K ﹤0.01% 2906
2022
Q2 		$11.8M Buy
1,989,887
+62,100
+3% +$420K ﹤0.01% 2905
2022
Q1 		$14.7M Sell
1,927,787
-144,258
-7% -$644K ﹤0.01% 2946
2021
Q4 		$5.62M Sell
2,072,045
-90,829
-4% -$310K ﹤0.01% 3541
2021
Q3 		$5.69M Sell
2,162,874
-6,099
-0.3% -$19.8K ﹤0.01% 3574
2021
Q2 		$8.96M Sell
2,168,973
-284,939
-12% -$1.29M ﹤0.01% 3263
2021
Q1 		$11.6M Buy
2,453,912
+36,261
+1% +$247K ﹤0.01% 3072
2020
Q4 		$17.3M Buy
2,417,651
+169,855
+8% +$1.63M ﹤0.01% 2714
2020
Q3 		$24M Sell
2,247,796
-23,492
-1% -$276K ﹤0.01% 2369
2020
Q2 		$28.7M Sell
2,271,288
-53,647
-2% -$624K ﹤0.01% 2260
2020
Q1 		$21.3M Buy
2,324,935
+231,887
+11% +$2.66M ﹤0.01% 2253
2019
Q4 		$29.2M Buy
2,093,048
+324,339
+18% +$4.71M ﹤0.01% 2348
2019
Q3 		$30.4M Buy
1,768,709
+196,847
+13% +$4.13M ﹤0.01% 2287
2019
Q2 		$42.8M Buy
1,571,862
+180,087
+13% +$4.12M ﹤0.01% 2186
2019
Q1 		$26.6M Buy
1,391,775
+8,015
+0.6% +$104K ﹤0.01% 2377
2018
Q4 		$13M Buy
1,383,760
+187,166
+16% +$2.4M ﹤0.01% 2645
2018
Q3 		$22.6M Buy
1,196,594
+113,442
+10% +$2.18M ﹤0.01% 2523
2018
Q2 		$21.2M Buy
1,083,152
+136,057
+14% +$2.69M ﹤0.01% 2538
2018
Q1 		$17.8M Sell
947,095
-3,807
-0.4% -$82.3K ﹤0.01% 2550
2017
Q4 		$15.8M Buy
950,902
+249,803
+36% +$4.28M ﹤0.01% 2598
2017
Q3 		$14.4M Buy
701,099
+270,334
+63% +$3.05M ﹤0.01% 2640
2017
Q2 		$3.86M Buy
430,765
+13,194
+3% +$133K ﹤0.01% 3183
2017
Q1 		$5.53M Buy
417,571
+35,447
+9% +$430K ﹤0.01% 3021
2016
Q4 		$4.87M Buy
382,124
+35,539
+10% +$456K ﹤0.01% 3078
2016
Q3 		$4.16M Buy
346,585
+33,992
+11% +$460K ﹤0.01% 3103
2016
Q2 		$3.44M Buy
312,593
+292,900
+1,487% +$3.58M ﹤0.01% 3158
2016
Q1 		$172K Buy
19,693
+1,718
+10% +$19.5K ﹤0.01% 3972
2015
Q4 		$394K Buy
+17,975
New +$414K ﹤0.01% 3889

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's VYGR Position: Q4 2025 in Review

Vanguard Group increased its Voyager Therapeutics (VYGR) stake by 0.51% in Q4 2025, buying an estimated $72.6K and bringing the position to 3,266,484 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2836.

Vanguard Group first reported a position in VYGR in Q4 2015 and has held it in 41 quarters since. The position peaked at $42.8M in Q2 2019. 125 funds tracked by Wall St. Rank hold VYGR as of Q4 2025.

  • Vanguard Group held 3,266,484 shares of Voyager Therapeutics worth $12.8M as of Q4 2025.
  • Vanguard Group bought 16,418 Voyager Therapeutics shares in Q4 2025, an estimated $72.6K.
  • Voyager Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2836 holding.
  • Vanguard Group first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 41 quarters since.
  • Vanguard Group's Voyager Therapeutics position peaked at $42.8M in Q2 2019.
  • 125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.